Nimbus in Agreement with Lilly for Small Molecule Activators of AMPK

 Nimbus eligible to receive up to $496 million, inclusive of research funding and potential milestone payments, in addition to royalties on net sales

AMPK activation is a promising strategy to treat disorders of dysregulated metabolism

 

Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, today announced it has entered into a research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (Lilly) for the development and commercialization of novel targeted therapies that activate a specific isoform of AMPK for the treatment of metabolic diseases.

Leveraging Nimbus’s computational drug discovery engine and expertise in structure-based drug design, Nimbus is uniquely positioned to develop isoform-selective small molecule activators of AMPK with potential therapeutic application to a broad range of metabolic disorders.

https://www.biospace.com/article/releases/nimbus-therapeutics-announces-research-collaboration-and-license-agreement-with-lilly-for-small-molecule-activators-of-ampk/?keywords=lilly